Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Viracta Therapeutics (Nasdaq: VIRX), a precision oncology firm, announced its upcoming presentation at the H.C. Wainwright BIOCONNECT Virtual Conference scheduled for January 10, 2022, starting at 7:00 a.m. ET. The pre-recorded webcast will be accessible on-demand at the Viracta website and will be archived for 90 days.

Viracta is focusing on virus-associated malignancies with its investigational drug, nanatinostat, currently in pivotal trials for EBV-positive lymphoma and other related cancers.

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference.

The pre-recorded webcast will be available for on-demand viewing beginning Monday, January 10, 2022, at 7:00 a.m. ET on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 90 days.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a pivotal Phase 2 clinical trial for EBV-positive (EBV⁺) lymphoma and a Phase 1b/2 trial in patients with EBV⁺ nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301453062.html

SOURCE Viracta Therapeutics, Inc.

FAQ

When is Viracta Therapeutics presenting at the H.C. Wainwright BIOCONNECT Virtual Conference?

Viracta Therapeutics is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022.

What time will the Viracta Therapeutics presentation be available?

The pre-recorded webcast will be available for on-demand viewing starting at 7:00 a.m. ET on January 10, 2022.

How long will the Viracta webcast remain available for viewing?

The webcast will be archived and available for 90 days after its initial release.

What is nanatinostat, and what trials is it involved in?

Nanatinostat is an investigational drug by Viracta Therapeutics, currently being evaluated in pivotal clinical trials for EBV-positive lymphoma and nasopharyngeal carcinoma.

What is the stock symbol for Viracta Therapeutics?

The stock symbol for Viracta Therapeutics is VIRX.